Trial reportEuropean journal of nuclear medicine and molecular imaging2012
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.
Trial report in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Trial
- Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [European journal of nuclear medicine and molecular imaging · 2019Trial
- Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.European journal of nuclear medicine and molecular imaging · 2013Trial
- Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Review
- Imaging of Bone Metastases in Breast Cancer.Seminars in nuclear medicine · 2022Review
- Novel applications of molecular imaging to guide breast cancer therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer.Cancers · 2021Article
- Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an ActivatingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Early Changes of the Standardized Uptake Values (SUVCancers · 2020Article
- PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [Molecular imaging and biology · 2019Article
- FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2019Review
- Article
- Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane.Targeted oncology · 2018Article
- Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers.PET clinics · 2018Review
- Functional and Hybrid Imaging of Bone Metastases.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2018Review
- Correlations between intravoxel incoherent motion diffusion-weighted MR imaging parameters andThe British journal of radiology · 2018Article
- Article
- Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.European journal of nuclear medicine and molecular imaging · 2017Article
- The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Article
- ¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Review
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this pilot study was to assess whether outcome in metastatic or recurrent breast cancer patients is related to metabolic response to endocrine therapy determined by (18)F-FDG PET/CT.
methodsThe study group comprised 22 patients with breast cancer (age 58 ± 11 years, mean ± SD) who were scheduled to receive endocrine therapy. They were systematically assessed by PET/CT at baseline and after a mean of 10 ± 4 weeks for evaluation of response after induction. All patients demonstrated FDG-avid lesions on the baseline PET/CT scan. The metabolic response was assessed according to EORTC criteria and based on the mean difference in SUV(max) between the two PET/CT scans, and the patients were classified into four groups: complete or partial metabolic response, or stable or progressive metabolic disease (CMR, PMR, SMD and PMD, respectively). All patients were followed in our institution.
resultsMetastatic sites were localized in bone (n = 15), lymph nodes (n = 11), chest wall (n = 3), breast (n = 5), lung (n = 3), soft tissue (n = 1) and liver (n = 1). PMR was observed in 11 patients (50%), SMD in 5 (23%) and PMD in 6 (27%). The median progression-free survival (PFS) times were 20, 27 and 6 months in the PMR, SMD and PMD groups, respectively. PFS in the SMD group differed from that in the PMR and SMD groups (p < 0.0001).
conclusionMetabolic response assessed by FDG PET/CT imaging in patients with metastatic breast cancer treated with endocrine therapy is predictive of the patients' PFS.
Indexed as
Identifiers
22183107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.